Is IL-33 useful to detect early stage of renal failure?

Renal Failure

Volumn 36, Issue 1, 2014, Pages 78-80

  Caner, Sedat ^a   Usluoǧullari, Celil Alper ^a   Balkan, Fevzi ^a   Büyükcam, Fatih ^b   Kaya, Cafer ^a   Saçikara, Muhammed ^a   Koca, Cemile ^a   Ersoy, Reyhan ^a   Çakir, Bekir ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Diabetes mellitus; Diagnosis; IL 33; Kidney; Renal failure

Indexed keywords

INTERLEUKIN 33;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE COURSE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; ALBUMINURIA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84889566625     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.832313     Document Type: Article

References (12)

1. Milovanovic M, Volarevic V, Radosavljevic G, et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res. 2012; 52(1-2):89-99.
2. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond). 2011;8(1):22.
3. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel "alarmin"? PloS One. 2008; 3(10):e3331.
4. Lamkanfi M, Dixit VM. IL-33 raises alarm. Immunity. 2009; 31(1):5-7.
5. Akcay A, Nguyen Q, He Z, et al. IL-33 exacerbates acute kidney injury. JASN. 2011;22(11):2057-2067.
6. Satirapoj B. Nephropathy in diabetes. Adv Exp Med Biol. 2012;771: 107-122.
7. Satirapoj B. Review on pathophysiology and treatment of diabetic kidney disease. J Med Assoc Thai. 2010;93 (Suppl 6):S228-S241.
8. McKenna K, Thompson C. Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus. Scot Med J. 1997;42(4):99-104.
9. Arababadi MK, Pourfathollah AA, Daneshmandi S, et al. Evaluation of relation between IL-4 and IFN-g polymorphisms and type 2 diabetes. IJBMS. 2009;12(2):100-104.
10. Miller AM, Purves D, McConnachie A, et al. Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PloS One. 2012;7(10):e47830.
11. Bao YS, Na SP, Zhang P, et al. Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease. J Clin Immunol. 2012; 32(3):587-594.
12. Musolino C, Allegra A, Profita M, et al. Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease. Brit J Haematol. 2013; 160(5):709-710.